2026 International Congress Archives - Page 119 of 208

Longitudinal Weight/BMI Trajectories and Their Clinical Impact on Parkinson’s Disease.

K. Sánchez-Ramírez, N. Sánchez-Lorenzo, A. Beltrán-Torres, M. Rocha-de-León, E. Ramírez-Benitez, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Longitudinal α-synuclein Seed Amplification Assay Analysis of PPMI Participants

L. Concha-Marambio, C. Gochanour, J. Yin, C. Farris, Y. Ma, D. Lafontant, T. Simuni, K. Marek, T. Tropea, D. Coughlin (San Diego, USA)
Loss of NAA60-mediated N-terminal acetylation cause primary brain calcification with disturbed Golgi- and phosphate-maintenance functions

A. Siggervåg, å. Bekkelund, C. Leerink, L. Alabdi, A. Khan, H. Aldhalaan, R. Helaby, O. Abuyousef, A. Melbye, N. Glomnes, J. Saraste, F. Alkuraya, H. Aksnes (Bergen, Norway)
Low-dose ketamine reduces dopamine 2 receptor-like agonist-induced dyskinesia in a preclinical model

T. Falk, R. Parmar, J. Meredith, J. Castro, E. Smith, M. Bartlett, S. Sherman (Tucson, USA)
Low-Intensity Treadmill Training Preserves Motor Function and Muscle Mass Through Mitochondrial and Antioxidant Regulation in a Rat Model of Parkinson’s Disease

TH. Yeh, CC. Chiu, HY. Huang (Taipei City, Taiwan)
LRRK2 G2019S Drives Lysosomal Lipid Remodeling and Inflammation in Human iPSC-Derived Microglia

M. Tziortziou, M. Jakubec, I. Goglia, K. Badanjak, P. Seibler, J. Penny, G. Dittmar, S. Pereira, P. Antony, E. Glaab, A. Grünewald (Esch-sur Alzette, Luxembourg)
LRRK2 in Focus: A Global Browser Linking Genetic Diversity to Functional Effects

S. Grant, V. van Midden, E. Fernandez, M. Cham, E. Sammler, D. Alessi, H. Morris, C. Blauwendraat, A. Singleton, L. Lange (Bethesda MD, USA)
LRRK2 Mutation Spectrum and Association Study in a Multi-ethnic Cohort of Malaysian Parkinson’s Disease Patients

K. Lim, J. Lim, M. Periñan, Y. Tay, T. Toh, L. Lit, A. Khairul Anuar, H. Ding, K. Ibrahim, A. Mawardi, Y. Chia, J. Ooi, T. Lim, J. Schee, Y. Beh, L. Screven, S. Bandres-Ciga, S. Lim, A. Tan, A. Ahmad-Annuar (Kuala Lumpur, Malaysia)
Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, May Improve Motor Complications in People with Parkinson’s Disease: Results from an 18-week open-label, Phase 1b Trial

AM. Højer, A. Cucca, C. Linander, L. Creuwels, M. Pedersen, D. Meulien (Copenhagen, Denmark)
Lysosomal polygenic risk score in Parkinson disease across populations.

W. Sun, K. Brockmann, C. Schulte, T. Gasser, M. Tan (Tübingen, Germany)